催化 (YL-0919),一个西格玛-1受体激动剂,通过增加mPFC中的BDNF来改善注意力
Yixin Yang1, Yue Zhang2, Xiaojuan Hou3
1Beijing Institute of Basic Medical Sciences, Beijing 100000, China.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
催化 (YL-0919),一个西格玛-1受体激动剂,增强了老鼠的注意力. 这种新型药物可能通过改善中部前额叶皮质中的大脑可塑性来为注意力缺陷提供一种新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前的注意力缺陷治疗有局限性,包括不良的副作用概况和可变的患者反应.
- 希皮化 (YL-0919),一种选择性西格玛-1受体激动剂,已经显示出更快的抗抑郁药效果的承诺.
研究的目的:
- 调查YL-0919的提高注意力的效果.
- 阐明YL-0919对注意力的作用的潜在机制.
主要方法:
- 五种选择的连续反应时间任务 (5-CSRTT) 用于在生理和皮质激素 (CORT) 暴露的条件下评估Sprague-Dawley (SD) 鼠的注意力.
- 对抑郁和焦虑的行为测试在暴露于CORT的老鼠中进行.
- 免疫光染色,西部染色和戈尔吉-考克斯染色被用来检查大脑中的分子和结构变化.
主要成果:
- YL-0919 (2.5和5毫克/公斤) 在生理上正常的老鼠中显著改善了注意力.
- 暴露于CORT会导致注意力缺陷,抑郁和焦虑类行为.
- YL-0919 (2.5和5毫克/公斤) 和SA4503 (3毫克/公斤) 缓解了暴露于CORT的老鼠的注意力缺陷.
- YL-0919增加了BDNF,PSD95和synapsin1的表达,并在中间前额叶皮层 (mPFC) 中增强了树突复杂性和脊柱密度.
结论:
- 作为西格玛-1受体激动剂,YL-0919有效地改善了在生理和压力引起的注意力缺陷状态中的注意力.
- 在mPFC中提高BDNF水平和改善树突复杂性是YL-0919提高注意力的关键机制.
- YL-0919代表了对注意力缺陷障碍的潜在新型治疗药物.
相关概念视频
01:30Attention-Deficit/Hyperactivity Disorder
23
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
23
01:25Adrenergic Agonists: Indirect-Acting Agents
1.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K